Results 61 to 70 of about 24,954,598 (334)
Molecular dynamics simulations are advancing the study of ribonucleic acid (RNA) and RNA‐conjugated molecules. These developments include improvements in force fields, long‐timescale dynamics, and coarse‐grained models, addressing limitations and refining methods.
Kanchan Yadav, Iksoo Jang, Jong Bum Lee
wiley +1 more source
Molecular epidemiological analysis of HIV-1 variants circulating in Russia in 1987—2015 [PDF]
Aim. To simultaneously analyze HIV-1 samples from all Russian regions to characterize the epidemiology of HIV infection in the country as a whole. Subjects and methods.
I A Lapovok+10 more
doaj +1 more source
Characterization of the longitudinal HIV-1 quasispecies evolution in HIV-1 infected individuals co-infected with Mycobacterium tuberculosis [PDF]
One of the earliest and most striking observations made about HIV is the extensive genetic variation that the virus has within individual hosts, particularly in the hypervariable regions of the env gene which is divided into 5 variable regions (V1-V5 ...
Leulebirhan, Tsigereda Biru
core
Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. [PDF]
OBJECTIVE: Trials of herpes simplex virus (HSV) suppressive therapy among HSV-2/HIV-1-infected individuals have reported an impact on plasma HIV-1 viral loads (PVLs). Our aim was to estimate the population-level impact of suppressive therapy on female-to-
Baggaley, Rebecca F+10 more
core +2 more sources
Islatravir‐loaded dissolving microarray patches (MAPs) provide a minimally invasive, long‐acting solution for HIV‐1 prevention and treatment. In rats, sustained islatravir delivery lasts up to three months, while in minipigs, efficacious plasma levels are detected for six days.
Qonita Kurnia Anjani+11 more
wiley +1 more source
A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?
Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells.
Ana Luiza Abdalla+2 more
doaj +1 more source
Despite great efforts have been made in the prevention and therapy of human immunodeficiency virus (HIV-1) infection, however the difficulty to eradicate latent viral reservoirs together with the emergence of multi-drug-resistant strains require the ...
Jenny Desantis+10 more
doaj +1 more source
The HIV-1 Protein Vpr Targets the Endoribonuclease Dicer for Proteasomal Degradation to Boost Macrophage Infection [PDF]
The HIV-1 protein Vpr enhances macrophage infection, triggers G2 cell cycle arrest, and targets cells for NK-cell killing. Vpr acts through the CRL4DCAF1 ubiquitin ligase complex to cause G2 arrest and trigger expression of NK ligands.
de Noronha, Carlos M.C.+6 more
core +2 more sources
AIMSPec‐LoC is a novel lab‐on‐a‐chip platform integrating size‐based extracellular vesicle (EVs) separation with label‐free Raman spectroscopy and AI‐powered classification via SKiNET. This high‐throughput, portable system enables real‐time, multiplexed molecular fingerprinting of EVs from biofluids, offering transformative potential for early, non ...
Emma Buchan+3 more
wiley +1 more source
Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection [PDF]
The majority of T cells encountered by HIV-1 are non-activated and do not readily allow productive infection. HIV-1 Vpr is highly abundant in progeny virions, and induces signalling and HIV-1 LTR transcription.
Kristin Höhne+9 more
doaj +1 more source